A research team at the Seville Biomedical Institute (IBis) has identified a new molecular mechanism that explains the high sensitivity of Ewing sarcoma (an aggressive bone cancer that mainly affects children and adolescents) to certain chemotherapy drugs, such as irinotecan. The results, published in the journal Oncogene, open the door to more personalized and effective strategies for treating this type of cancer.
This article was originally published on MedicalXpress.com